GNMSF News and Press, Genmab A/S Dkk From 02/09/22

Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...

Pharma/biotechnology is the most attractive healthcare subsector. Life science tools have performed the best in one year, but are overvalued now. Focus on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For November

Genmab A/S (GMAB) Q3 2021 Results Conference Call November 10, 2021 12:00 PM ET Company Participants Jan van de Winkel - President and CEO Anthony Pagano - CFO Judith Klimovsky - Chief Development Officer Anthony Mancini - COO Conference Call Participants Wimal Kapadia - Bernstein James Gordo...

The following slide deck was published by Genmab A/S in conjunction with their 2021 Q3 earnings call. For further details see: Genmab A/S 2021 Q3 - Results - Earnings Call Presentation

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IBB. A list of cheap stocks. For further details see: IBB: Healthcare Dashboard For October

Harding Loevner is an investment manager that invests primarily in publicly traded global equities. We were founded in 1989 by former managers for the Rockefeller family. Harding Loevner is a Delaware limited partnership. We operate independently of Affiliated Managers Group. The Glob...

After the recent era of value expansion due to the pandemic and fiscal policy, the use of unbiased rankings may allow for long-term success. As valuations come back down to historical levels, as very few would claim they will stay elevated perpetually, holding the right stocks will be...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IDNA. A list of cheap stocks. For further details see: IDNA: Healthcare Dashboard For September

Genmab currently has aided and/or partnered in the development of four FDA approved monoclonal antibody therapies. While not the owners, developers, or manufacturers of most of these therapies, the company earns money via licensing of their novel and innovative technology. This wi...

Genmab A/S (GMAB) Q2 2021 Results Conference Call August 11, 2021 12:00 PM ET Company Participants Jan van de Winkel - President and CEO Anthony Pagano - CFO Judith Klimovsky - Chief Development Officer Anthony Mancini - COO Tahi Ahmadi - Chief Medical Officer Conference Call Participants Wim...